Crinetics Pharmaceuticals (CRNX) Q3 2025 earnings summary

Executive summary

• PALSONIFY (paltusotine) launched in the U.S. after FDA approval for acromegaly, showing strong early commercial momentum, broad prescriber engagement, and positive reimbursement trends.

• Multiple late-stage clinical trials are advancing for carcinoid syndrome, congenital adrenal hyperplasia (CAH), ACTH-dependent Cushing's syndrome, and neuroendocrine tumors, with key data readouts and regulatory milestones expected in the next 18–24 months.

• The company is executing a three-phase launch strategy for PALSONIFY, focusing on switch patients, re-engaging lapsed patients, and improving diagnosis rates.

• European review of PALSONIFY is ongoing, with a potential EMA decision in H1 2026.

• Cash runway is projected into 2029, supporting commercialization and pipeline milestones.

Financial highlights

• Q3 2025 revenue was $0.1 million, primarily from licensing agreements; no product revenue recognized due to timing of approval.

• R&D expenses were $90.5 million in Q3 2025, up significantly year-over-year, reflecting increased clinical activity and personnel.

• SG&A expenses rose to $52.3 million in Q3 2025, driven by launch investments and commercial team growth.

• Net loss for Q3 2025 was $130.1 million, with net loss per share at $1.38.

• Cash, cash equivalents, and investments totaled $1.1 billion as of September 30, 2025.

Outlook and guidance

• Cash runway expected to fund operations into 2029, with 2025 net cash used in operations guided at $340–$370 million.

• Launch metrics for PALSONIFY, including revenue and prescriber numbers, will be provided after a full quarter in Q1 2026.

• Multiple late-stage clinical milestones anticipated in Q4 2025 and early 2026, including Phase 3 trial initiations and data readouts.

• Expects increased expenses as product revenues ramp up and pipeline advances.

• Expectation of payer formulary coverage for PALSONIFY in most plans within 6–9 months.